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Abstract 
Introduction: Dysregulation of adipokine secretion and action is a characteristic feature of obesity and a key clinical feature of Cushing’s 
syndrome (CS). We have investigated whether endogenous glucocorticoid excess influences adipose tissue-derived gene expression.
Material and methods: mRNA expression of adipokines; adiponectin, resistin, tumour necrosis factor-a, interleukin-6 (IL-6), angiotensino-
gen (AGT), plasminogen activator inhibitor type 1, retinol binding protein 4, visfatin, and cystatin C was assessed by quantitative real-time 
RT-PCR in visceral adipose tissue removed during abdominal surgery of eight patients with CS, and six control patients.
Results: We did not find any significant difference in the investigated genes; however, the almost significant overexpression of AGT and 
underexpression of IL-6 might be noteworthy (p = 0.06 in both cases).  
Conclusions: No significant differences were found in the expression of the investigated genes known as cardiometabolic risk factors. This 
indicates that there are no major differences between endogenous hypercortisolism or diet-induced obesity regarding the expression of 
adipokines involved in cardiometabolic disorders. However, the difference in AGT and IL-6 expression might be included in pathways 
affecting fat distribution in CS. (Endokrynol Pol 2019; 70 (2): 131–134)
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Introduction 
The pathogenesis of obesity is an intensively studied 
research field because of its high prevalence and severe 
comorbidities. Especially visceral/abdominal obesity has 
a strong link to the pathophysiology of comorbidities 
(insulin resistance, impaired glucose tolerance or type 
2 diabetes, dyslipidaemia, inflammatory disorders, 
hypercoagulability, hypertension, atherosclerosis, or 
other cardiovascular disorders) [1]. One of the typical 
features of Cushing’s syndrome (CS) is central obesity. 
CS is the consequence of chronic endogenous glucocor-
ticoid (GC) excess, and the above-mentioned associated 
disorders can also join the list of its clinical properties. 
Glucocorticoids are involved in several physiologi-
cal processes, among others in the regulation of food 
intake, gluco- and adipogenesis, strongly influencing 
energy metabolism and body weight [2]. GCs have 
several targets in lipid metabolism, are powerful 
regulators of fat deposition and distribution, and are 
essential in adipogenesis and adipocyte differentiation 
[3]. Glucocorticoids might play an important role in the 
development of visceral adiposity [4]. White adipose 
tissue secrets a large number of adipokines, which 
have effects on inflammation/oxidative stress (leptin, 
adiponectin, resistin), energy wasting (leptin, adipo-
nectin), insulin signalling (adiponectin, leptin, visfatin), 
endothelial dysfunction (visfatin), and vascular damage 
(adiponectin, leptin, resistin), which are relevant in obe-
sity. Obesity disrupts the dynamic role of adipocytes, 
resulting in altered production of adipokines. This is 
involved in the well-known obesity-related complica-
tions. In central obesity altered adipokine secretion has 
been observed. Both in vitro and in vivo studies have 
shown a relationship between cortisol and adipokines 
[5]. Altered cytokine levels in CS lead to increased 
mortality [5]. We have to note that mainly circulating 
cytokine levels have been measured in these studies, 
or if gene expression analysis was performed, it was 
done on subcutaneous adipose tissue samples [6]. We 
have therefore investigated the gene expression of 
several adipokines, which have been shown to have 
a major influence on cardiovascular complications, and 
are produced mainly by visceral but not subcutaneous 
adipose tissue [adiponectin (ADIPDQ), resistin (RETN), 
tumour necrosis factor-a (TNF-a), interleukin-6 (IL-6), 
angiotensinogen (AGT), plasminogen activator inhibitor 
type 1 (PAI-1), retinol binding protein 4 (RBP4), visfatin, 
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Total RNA (10 ng) was reverse transcribed to cDNA using a High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA, USA). qRT-PCR was performed by TaqMan Fast 
Universal PCR Master Mix (2x) (Applied Biosystems) on a 7500 
Fast Real-Time PCR System (Applied Biosystems) according to 
the manufacturer’s instruction. All samples were run in triplicate.
Normalised signal levels for each gene were calculated using the 
comparative cycle threshold (ddCT) method relative to HPRT1 
following the instructions of the manufacturer (SDS Program, 
Applied Biosystems).
Statistical analysis
For the identification of differentially expressed genes between 
Cushing’s adipose tissue groups and control adipose tissue groups, 
F-test was used followed by t-test. p values < 0.05 were considered 
statistically significant.
Results
Nine genes (ADIPOQ, RETN, TNF-a, IL6, AGT, SER-
PINE-1, RBP4, NAMPT, cystatin C) were selected based 
on literature data, and their expression was studied 
by qRT-PCR. None of these genes turned out to be 
significantly differentially expressed between CS and 
normal samples; however, the expression of two genes 
was almost significant. AGT was overexpressed in Cush-
ing’s adipose samples versus control samples (p = 0.06). 
Underexpression of IL-6 was validated in Cushing’s adi-
pose samples versus control samples (p = 0.06) (Fig. 1).
RETN could not be measured in tissue samples, and 
the expression of TNF-a only exceeded the detection 
limit in some samples.
Discussion
Adipose tissue plays not only a role in energy storage, 
but it is also an endocrine organ that secretes numer-
cystatin C (CST3)] in visceral adipose tissue of patients 
with CS and control subjects.
Material and methods
Patients 
Altogether 14 obese patients (BMI > 30 kg/m2) were involved in this 
study: eight patients with adrenal Cushing’s syndrome undergoing 
adrenalectomy and six control patients undergoing elective abdomi-
nal surgery (such as cholecystectomy, appendectomy). To avoid the 
gender differences of gene expression, we performed an only female 
study. The control patients had no symptoms and laboratory signs of 
hypercortisolism. The diagnosis of Cushing’s syndrome was made on 
the basis of clinical appearance, laboratory testing (overnight and low-
dose dexamethasone test, ACTH) and imaging. Table I summarises the 
clinical characteristics of the patients. There was no significant dif-
ference between the two groups in terms of age or body mass index. 
The study was approved by the local research ethics committee, and 
all patients involved gave written, informed consent in accordance 
with the guidelines in the declaration of Helsinki. 
Tissue handling
Abdominal adipose tissue was taken by excision at the end of the 
surgical intervention. The tissue samples were immediately frozen 
on dry ice in the operating room for RNA extraction and transferred 
to the laboratory. Samples were stored at –80°C until use.
RNA isolation
Total RNA extraction from fresh-frozen, 500 µl human adipose tissues 
was performed after tissue homogenisation with a Qiagen miRNeasy 
Mini Kit (Qiagen GmbH, Hilden, Germany) according to the instruc-
tions of the manufacturer. On-column DNase digestion was carried 
out with the RNase-Free DNase set (Qiagen GmbH, Hilden, Germany).
RNA quantity was determined by NanoDrop 1000 Spectrophotom-
eter (Thermo Fisher Scientific Inc., Waltham, MA, USA), and then 
RNA integrity was examined by an Agilent 2100 Bioanalyzer System 
(Agilent Technologies Inc., Santa Clara, CA, USA). Samples with 
an RNA integrity number (RIN) above 6.0 were used for further 
analysis. RNA was stored at –80 °C until use.
Quantitative reverse-transcription polymerase chain reaction (qRT-
PCR) TaqMan Gene Expression Assays (Applied Biosystems, Foster 
City, CA, USA) were used as follows: ADIPOQ (00605917), RETN 
(00220767), TNF-a (01113624), IL6 (00985639), AGT (01586213), 
SERPINE 1 (01126606), RBP4 (00198830), NAMPT (00237184), CST3 
(00264679).
Hypoxanthine phosphoribosyltransferase 1 (HPRT1) (02800695) 
was used as a reference gene (Hurtado 2010). 
Table I. Clinical characteristics of the patients
Patients with CS Control patients
Number of patients/ 
/gender
8 females 6 females
BMI 35.4 ± 0.6 34.6 ± 0.4 
Age at surgery 48 ± 8 years 47 ± 7 years
Size of the adrenal gland 
(CT)
23 ± 8 mm NA
Cortisol (after 1 mg 
dexamethasone)
227 ± 37 nmol/l 28 ± 7 nmol/l 
ACTH (10–60 pg/ml) 6 ± 3 pg/ml NA
CS — Cushing’s syndrome; BMI — body mass index; CT — computed 
tomography; ACTH — adrenocorticotropic hormone; NA — not available
Figure 1. Relative expression of different adipokine mRNAs in 
Cushing’s syndrome (n = 8) compared to controls  (n = 6) by 
qRT-PCR.  Dark bars represent Cushing’s syndrome patients, 
whereas white bars are controls.  Mean ±  SD of –dCt values 
of mRNAs relative to HPRT1 are shown
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ous hormones and bioactive molecules, the so-called 
“adipokines”. 
Several data suggest meaningful influence of GCs 
on the expression of different adipokines. In the cur-
rent study we have investigated the expression level 
of several adipokines in the visceral adipose tissue 
of patients with CS and control obese patients, to in-
vestigate the potential relevance of adipokines in the 
abdominal obesity characteristic for CS. Genes have 
been selected based on literature data [5]. Below, we 
briefly summarise the most important characteristics of 
the studied adipokines. Two adipokines showed almost 
significant alterations in expression in our small cohort.
Adipocytes are the most important source of angio-
tensinogen. Transient or chronic overexpression of AGT 
in adipose tissue favours lipogenesis in adipocytes and 
leads to a vicious circle whereby adipose tissue develop-
ment is further increased. AGT level is higher in obese 
than lean subjects and the AGT-mRNA expression is 
upregulated, especially in omental adipose tissue in 
obese patients [7, 8]. We showed an almost significant 
overexpression of AGT in visceral adipose tissue of 
CS patients compared to obese controls. This finding, 
taking into consideration that in obese patients the 
AGT-mRNA expression is already upregulated, might 
suggest that GCs might play a role in stimulation of AGT 
production. The adipose tissue expansion needs ap-
propriate blood supply providing O2, nutrition, growth 
factors, hormones, and stem cells [9]. Angiogenesis is 
an important step in adipose tissue remodelling [10]. 
AGT is known to be involved also in angiogenesis [11, 
12]. The almost significant overexpression of AGT might 
be linked to angiogenesis and thereby implicated in 
visceral adipose tissue expansion. 
mRNA expression studies show that adipocytes 
also can synthesise both tumour necrosis factor alpha 
and several interleukins, among them IL-6. TNF-a and 
IL-6 reduce lipid accumulation in adipose tissue, have 
some trophic effects, regulate insulin signalling [13], 
and are prominent contributors in the pathogenesis of 
atherosclerosis [5].  In our study, IL-6 expression was 
almost significantly down-regulated in patients with 
CS, compared to the control group. There are con-
flicting data on IL-6 levels in CS in the literature. The 
plasma levels of IL-6 have been found to be significantly 
higher with active CS women than in controls [14]. In 
contrast, in another study no significant difference 
was found in patients with CS and controls, but after 
surgery for Cushing’s syndrome, IL-6 levels rose, which 
could be associated with the well-known suppressive 
action of glucocorticoids on IL-6 secretion [15]. The 
anti-inflammatory effect of GCs might be related to 
the suppression of tissue IL-6 expression in our study. 
Moreover, the expression of tissue cytokines does not 
always parallel the serum concentrations [16]. It has 
already been shown that GCs decrease inflammatory 
cytokines, such as IL-6 and TNF-a, in adipose tissue 
samples [17, 18]. 
Regarding the following genes, we found no differ-
ence in their expression in the CS group vs. the control 
group.
Plasminogen activator inhibitor type 1 is involved 
in vascular homeostasis [5], and it might play a role 
in the hypercoagulable and hypofibrinolytic state ob-
served in CS. In different studies, elevated PAI-I level 
has been found in CS subjects compared to healthy 
controls [19–21]. We found no difference in the PAI-1 
gene expression level in CS patients compared to obese 
controls, but we have to note that in our study the 
control subjects were BMI-matched obese patients and 
PAI-1 is known to be elevated in obesity, while in the 
other studies they were healthy controls. 
Retinol binding protein 4 (RBP4) elevation was 
shown to cause adipose tissue inflammation by acti-
vating innate immunity [22]. Insulin resistance, which 
is a common complication of CS, is associated with 
adipose tissue inflammation. Although dexamethasone 
was shown to induce genes related to acute-phase 
response or innate immunity, such as RBP4 [23], we 
did not find any difference in RBP4 expression in our 
cohort. 
Regarding the level of other adipokines (adiponec-
tin, resistin, visfatin, and cystatin C), of which gene 
expression level we did not find any difference, there 
are contradictory results based on the few studies per-
formed on humans. Cortisol excess has either no effect 
or it can influence the level of these adipokines in some 
settings [14, 24–27].
Fat accumulation in visceral depots is associated 
with an increased risk of metabolic disease. Hyper-
cortisolism is associated with visceral obesity. Glu-
cocorticoids have an effect on adipocyte metabolic, 
endocrine, and immune functions. There are some 
known molecular mechanisms that mediate depot 
differences in CS (11b-HSD1, AMPK, leptin, and lipo-
protein lipase demonstrated differences in sensitivity 
and responsiveness to GC effect) [28–31], but the mo-
lecular mechanism by which GCs exert their effect on 
adipose tissue is not fully understood. We performed 
our study directly on visceral adipose tissue of patients 
with hypercortisolism and on control subjects, and we 
did not find any difference between the two groups 
in the investigated genes.
Conclusions
Dysregulated adipokine secretion and action in obe-
sity play an important role in the development of 
134
O
R
IG
IN
A
L
 P
A
P
E
R
Adropin in women with polycystic ovary syndrome Judit Denes et al.
cardiometabolic disorders. Cushing’s syndrome with 
endogenous glucocorticoid excess is associated with 
central obesity. Glucocorticoids regulate differentiation, 
distribution, endocrine function, and metabolism of 
adipose tissue. Previous studies have found an imbal-
ance in adipokine production in conditions with central 
obesity, such as Cushing’s syndrome. In these studies, 
mainly circulating cytokine levels were measured, 
while we investigated the gene expression of several 
adipokines produced mainly by visceral adipose tis-
sue. We did not show any difference in the genes 
that are marked as cardiometabolic risk factors. This 
indicates that there are no major differences between 
endogenous hypercortisolism or diet-induced obesity 
regarding the pathogenesis of complications.
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